ABSTRACT:
A reliable and stability-indicating RP-HPLC method was successfully developed and validated for the simultaneous quantification of Bisoprolol Fumarate and Dapagliflozin Propanediol Monohydrate in a synthetic formulation, following ICH guidelines. Chromatographic separation was achieved using a mobile phase composed of 0.1% triethylamine and acetonitrile in a 66:33 ratio (v/v), adjusted to pH 3 with orthophosphoric acid. Analysis was conducted in isocratic mode on an Agilent Zorbax ODS C18 column (150 mm × 4.6 mm, 5 µm) with a flow rate of 1.5 ml/min and detection at 225 nm. Bisoprolol and Dapagliflozin were retained at 2.99 min and 9.35 min, respectively. System suitability parameters, such as theoretical plates, resolution, and tailing factor, met standard acceptance criteria. The method demonstrated excellent sensitivity with LOD values of 0.99 µg/ml for Bisoprolol and 3.02 µg/ml for Dapagliflozin, and LOQ values of 1.06 µg/ml and 3.23 µg/ml, respectively. Linearity was observed within the 5–15 µg/ml range, with correlation coefficients (r²) of 0.9995 and 0.9994. Accuracy studies showed recovery rates between 98.3–101.2% for Bisoprolol and 100.4–101.5% for Dapagliflozin. The method was validated under stress conditions including acidic, alkaline, oxidative, photolytic, and thermal environments, confirming its effectiveness as a stability-indicating analytical approach.
Cite this article:
Disha H. Joshi, Jimish R. Patel. Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Dapagliflozin Propanediol Monohydrate and Bisoprolol Fumarate in Synthetic Mixture. Asian Journal of Pharmaceutical Research.2025; 15(4):355-3. doi: 10.52711/2231-5691.2025.00055
Cite(Electronic):
Disha H. Joshi, Jimish R. Patel. Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Dapagliflozin Propanediol Monohydrate and Bisoprolol Fumarate in Synthetic Mixture. Asian Journal of Pharmaceutical Research.2025; 15(4):355-3. doi: 10.52711/2231-5691.2025.00055 Available on: https://asianjpr.com/AbstractView.aspx?PID=2025-15-4-1
REFERENCES:
1. Tanai E, Frantz S. Pathophysiology of heart failure. Compr Physiol. 2016; 6: 187–214.
2. Central Drugs Standard Control Organization. FDC approved drug combination of Dapagliflozin and bisoprolol fumarate [Internet]. 2023 Aug 11 [cited 2025 May 21]. Available from: https://cdsco.gov.in/opencms/opencms/en/Approval_new/CT-Approvals/
3. Ravinandan AP, Vishwas HN, Hosur SS, Mustafa GM, Kavya HB. Dapagliflozin: a molecule for type-2 diabetes mellitus. Int J Pharm Chem Anal. 2022; 9(4):155–6.
4. CDSCO. Dapagliflozin Propanediol Monohydrate [Internet]. 2024 [cited 2025 May 21]. Available from: https://cdsco.gov.in/opencms/opencms/en/Approval_new/CT-Approvals/
5. Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Acta Cardiol. 2010; 65(5):565–70.
6. PubChem [Internet]. Bethesda (MD): National Center for Biotechnology Information; 2004– [cited 2025 Mar 22]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Bisoprolol-Fumarate
7. Patel JR, Bedi HS, Middha A, Prajapati LM, Parmar VK. RP-HPLC method for estimation of nitazoxanide in oral suspension formulation. Der Pharma Chemica. 2012; 4(3):1140-1144.
8. Manimala M, Reddy RK, Rani HD. Development and validation of UV spectrophotometric and RP-HPLC methods for the determination of bisoprolol fumarate in pure and pharmaceutical dosage form. World J Pharm Res. 2013; 2:3165–71.
9. RB Kakde, VH Kotak, DL Kale. Estimation of Bisoprolol Fumarate in Pharmaceutical Preparations by HPTLC. Asian J. Research Chem. 2008; 1(2): 70-73.
10. Laxman M. Prajapati, Anjali Patel, Jimish R. Patel, Amit K. Joshi, Mohammadali Kharodiya. High Performance Thin Layer Chromatography Method for Simultaneous Estimation of Cefepime Hydrochloride and Sulbactam Sodium. Asian J. Pharm. Ana. 2016; 6(4): 207-212.
11. Tripathy SN, Swain S, Jena BR, Sahu A. New validated UV spectrophotometric method for the quantification of bisoprolol fumarate in its pharmaceutical dosage form. Acta Sci Pharm Sci. 2023; 7(2): 4–9.
12. Todevska EL, Piponski M, Stefova M. Development and validation of an analytical method for the determination of related substances in bisoprolol fumarate in dosage forms by HPLC-UV-DAD. Maced J Chem Chem Eng. 2021; 40:263–76.
13. Bhavyasri K, Goud JS, Sewthasri R, Sumakanth M. Development and validation of stability indicating RP-HPLC method for the estimation of bisoprolol fumarate in bulk and pharmaceutical dosage form. Int J Pharm Phytopharmacol Res. 2020; 10(4): 49–70.
14. Sandip A Telavane, Seema Kothari, Manohar V. Lokhande. Method of Validation for Residual Solvents in Bisoprolol Fumarate by GC Technique. Asian Journal of Pharmaceutical Research. 2021; 11(3):147-5.
15. Kakde RB, Kotak VH, Kale DL. Estimation of bisoprolol fumarate in pharmaceutical preparations by HPTLC. Asian J Res Chem. 2008; 1(2):70–3.
16. Mahu SC, Space AF, Ciobanu C, Hancianu M, Agoroaei L, Butnar E. Quantitative determination of bisoprolol fumarate by HPLC. Rev Chim (Bucharest). 2016; 67(3): 414–7.
17. RB Kakde, VH Kotak, AG Barsagade, NK Chaudhary, DL Kale. Spectrophotometric Method for Simultaneous Estimation of Amlodipine Besylate and Bisoprolol Fumarate in Pharmaceutical Preparations. Research J. Pharm. and Tech. 2008; 1(4): 513-515.
18. Bhusnure OG, Dongare RB, Gholve SB, Rajmane TM, Munde AB, Giram PS. Development and validation of UV spectroscopic method for the determination of bisoprolol fumarate tablets. Int J Pharm Biol Sci. 2018; 8(2): 338–44.
19. United States Pharmacopeia-National Formulary. Dapagliflozin Propanediol. Rockville (MD): USP; 2023 Dec. doi:10.31003/USPNF_M9215_02_01
20. Sarkar S, Patel VP. Method development and validation of dapagliflozin drug in bulk and tablet dosage form by RP-HPLC. Int J Pharm Res Health Sci. 2017; 5(4): 1755–9.
21. Sumaa BV, Deveswaran RB, Shenoy P. A new high-performance thin-layer chromatographic method development and validation of dapagliflozin in bulk and tablet dosage form. Int J Pharm Pharm Sci. 2019; 11(8): 58–63.
22. Manoharan G, Ismaiel AM, Ahmed ZM. Estimation of dapagliflozin in raw and tablet formulation. Chem Res J. 2018; 3(2): 159–64.
23. Vinutha Kommineni, K.P.R. Chowdary, S.V.U.M. Prasad. Formulation of Dapagliflozin and Saxagliptin Tablets and In vitro Evaluation by RP-HPLC Method. Asian J. Pharm. Ana. 2019; 9(2): 93-98. doi: 10.5958/2231-5675.2019.00018.8
24. Sayali S. More, Sandeep S. Sonawane, Santosh S. Chhajed, Sanjay J. Kshirsagar. Development and Validation of RP-HPLC Method for Simultaneous Estimation of Saxagliptin and Dapagliflozin in Tablets. Asian J. Pharm. Tech. 2018; 8 (3):145-148.
25. Chavhan PG, Patil SA, Pawar SP. Analytical method development and validation of dapagliflozin in bulk drug and pharmaceutical dosage form by U-HPLC method. Int J Pharm Res Technol. 2024: 661–9.
26. Navya Sree V, Bhavyasri K, Sumakanth M, Swethasri R. Estimation of dapagliflozin in pure and marketed formulation by validated reverse phase-high performance liquid chromatographic method. Int J Life Sci Pharm Res. 2020; 10(1):70–84.
27. Bhagwat JB. Quantitative estimation of dapagliflozin in blood plasma by using UV spectroscopy. Pharm Anal Acta. 2010; 10(2): 608.
28. Sanagapati M, Dhanalakshmi K, Reddy NG, Kavitha B. Method development and validation of dapagliflozin API by UV spectroscopy. Int J Pharm Sci Rev Res. 2014; 26(1): 270–7.
29. Debata J, Kumar S, Jha SK, Khan A. A new RP-HPLC method development and validation of dapagliflozin in bulk and tablet dosage form. Int J Drug Dev Res. 2017; 9(2):48–51.
30. U.S. Food and Drug Administration. Guidance for industry Q1A(R2): stability testing of new drug substances and products [Internet]. 2003 [cited 2025 May 21]. Available from: https://www.fda.gov/media/71707/download
31. Iram F, Iqbal MA, Husain A. Forced degradation studies. J Anal Pharm Res. 2016; 3(9).
32. Ueyama E, Takahashi F, Ohashi J, Konse T, Kishi N, Kano K. Mechanistic study on degradation of azelnidipine solution under radical initiator-based oxidative conditions. J Pharm Biomed Anal. 2012; 61: 277–83.